Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Reduced Efficacy of COVID-19 Vaccination in Immunocompromised Patients

Web Exclusives

It has been more than a year and a half since the World Health Organization first declared COVID-19 a pandemic disease.1 Remarkably, during that time several mRNA vaccines have been approved for use in the United States, each with a good safety profile and high efficacy in preventing infection by the SARS-CoV-2 virus.1

Although doctors knew early in the pandemic that immunocompromised patients were at higher risk of severe disease and death from COVID-19, patients with impaired immune systems were excluded from participating in the initial vaccine clinical trials.1 Recent analyses of real-world patients who received COVID-19 vaccination have shown that some immunocompromised patients, including those with chronic lymphocytic leukemia (CLL), are less likely to form antibodies that would protect them from COVID-19.1-4

In a recent clinical trial, investigators sought to evaluate the safety and ability of 2 doses of Pfizer-BioNTech’s mRNA vaccine to promote the production of protective antibodies against SARS-CoV-2 in immunocompromised patients.1 Five groups of adult patients were accepted in the study, including those with a chronically weakened immune system, and those whose immune systems had been compromised by 1 of the following: HIV infection; receipt of a stem-cell transplant or chimeric antigen receptor T-cell (CAR-T) therapy; solid organ transplant; or CLL.1 For comparison, a group of healthy individuals who were not immunocompromised were also included.1

Of the 539 subjects included in this study, 97.4% received both doses of the vaccine.1 The 14 subjects who did not receive a second dose included 9 who were diagnosed with COVID-19 between the 2 doses, and 5 who had side effects that prevented completion of the vaccination series.1 Side effects in the study were similar between the immunocompromised patients and healthy subjects and were generally mild in severity.1 However, 1 patient who had previously received a stem-cell transplant and CAR-T therapy had a serious reaction 4 days after their first vaccine dose, and subsequently died of lung failure 2 months later.1

Immunocompromised patients were less likely to form an effective antibody response after full vaccination compared with the healthy subjects. Whereas all healthy subjects (100%) showed antibodies to SARS-CoV-2, efficacy was only approximately 72% in immunocompromised patients.1 Vaccination was least effective in patients who had received a solid organ transplant (about 43% showed antibodies) and most effective in patients with HIV (approximately 98% produced antibodies).1

Looking at patients with CLL, approximately 63% formed antibodies after 2 vaccine doses, although the likelihood of having an effective immune response varied depending on whether they were receiving current CLL treatment.1 Specifically, only approximately 27% of patients who were receiving ongoing treatment with ibrutinib developed antibodies after vaccination, whereas vaccines were approximately 56% effective in patients who were no longer being treated with ibrutinib.1 For patients undergoing watchful waiting, or who were off long-term chemoimmunotherapy, COVID-19 vaccination was more than 80% effective.1

The preliminary results from this study suggest that 2-dose COVID-19 vaccination is generally safe for immunocompromised patients, although the efficacy is substantially lower than in healthy individuals.1 Specific vaccination strategies, such as adding a third booster dose,* or pausing ongoing therapies may be required to adequately protect these patients.1

*Note that as of September 2021, the US Centers for Disease Control and Prevention has recommended a third dose booster for immunocompromised patients who have already received 2 doses of the Pfizer-BioNTech COVID-19 vaccine.5,6

References

  1. Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. medRxiv. Published September 14, 2021. www.medrxiv.org/content/10.1101/2021.09.07.21263206v2. Accessed October 18, 2021.
  2. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165-3173.
  3. Diefenbach C, Caro J, Koide A, et al. Impaired humoral immunity to SARS-CoV-2 vaccination in non-hodgkin lymphoma and CLL patients. medRxiv. Published June 3, 2021. www.medrxiv.org/content/10.1101/2021.06.02.21257804v1. Accessed October 18, 2021.
  4. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96:1195-1203.
  5. Centers for Disease Control and Prevention. Who is eligible for a COVID-19 vaccine booster shot? Updated October 7, 2021. www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html. Accessed September 27, 2021.
  6. Centers for Disease Control and Prevention. People with certain medical conditions. Updated October 14, 2021. www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed October 18, 2021.

Recommended For You